Pharmaceutical Commerce: Time to ax copay accumulators?
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
For patients who are enrolled in private health insurance plans with copay accumulator programs, the value of third-party contributions—such as the value of manufacturer coupons or grants from charitable patient assistance foundations—don’t count toward patients’ deductibles or annual out-of-pocket limits.
In this column for Pharmaceutical Commerce, PAN’s President and CEO, Kevin L. Hagan, and Chief Advocacy and Engagement Officer, Amy Niles, outline how copay accumulator programs are harmful to patients and why they should be banned.